Lidocaine-Induced Brugada Syndrome Phenotype Linked to a Novel Double Mutation in the Cardiac Sodium Channel

Hector M. Barajas-Martínez,* Dan Hu,* Jonathan M. Cordeiro, Yuesheng Wu, Richard J. Kovacs, Henry Meltser, Hong Kui, Burashnikov Elena, Ramon Brugada, Charles Antzelevitch, Robert Dumaine

Abstract—Brugada syndrome has been linked to mutations in SCN5A. Agents that dissociate slowly from the sodium channel such as flecainide and ajmaline unmask the Brugada syndrome electrocardiogram and precipitate ventricular tachycardia/fibrillation. Lidocaine, an agent with rapid dissociation kinetics, has previously been shown to exert no effect in patients with Brugada syndrome. We characterized a novel double mutation of SCN5A (V232I in DI-S4+L1308F in DIII-S4) identified in a rare case of lidocaine (1 mg/kg)-induced Brugada syndrome. We studied lidocaine blockade of I Na generated by wild-type and V232I+L1308F mutant cardiac sodium channels expressed in mammalian TSA201 cells using patch clamp techniques. Despite no significant difference in steady-state gating parameters between V232I+L1308F and wild-type sodium currents at baseline, use-dependent inhibition of I Na by lidocaine was more pronounced in V232I+L1308F versus wild-type (73.0±0.1% versus 18.23±0.04% at 10 μmol/L measured at 10 Hz, respectively). A dose of 10 μmol/L lidocaine also caused a more negative shift of steady-state inactivation in V232I+L1308F versus wild-type (−14.1±0.3 mV and −4.8±0.3 mV, respectively). The individual mutations produced a much less accentuated effect. We report the first case of lidocaine-induced Brugada electrocardiogram phenotype. The double mutation in SCN5A, V232I, and L1308F alters the affinity of the cardiac sodium channel for lidocaine such that the drug assumes Class IC characteristics with potent use-dependent block of the sodium channel. Our results demonstrate an additive effect of the 2 missense mutations to sensitize the sodium channel to lidocaine. These findings suggest caution when treating patients carrying such genetic variations with Class I antiarrhythmic drugs. (Circ Res. 2008;103:396-404.)

Key Words: arrhythmia (mechanisms) | Brugada syndrome | ion channels | Na channels | sudden death

Brugada syndrome (BrS) is an inherited cardiac disease characterized by an ST segment elevation in the right precordial electrocardiogram (ECG) leads (V1 to V3) and a high incidence of sudden death.1,2 The electrocardiographic manifestation of the syndrome is often concealed but can be unmasked using sodium channel blockers.3,4 Sodium channel blockers with slow dissociation kinetics such as flecainide and ajmaline are known to unmask the BrS ECG phenotype as well as precipitating ventricular tachycardia/fibrillation. Lidocaine, a Class IB antiarrhythmic agent, with rapid dissociation kinetics has little or no effect on the ST segment in patients with BrS.4 This study presents a rare case of lidocaine-induced BrS phenotype with a unique novel double mutation of SCN5A capable of altering the drug-receptor interaction so as to confer on lidocaine profound use-dependent sodium channel-blocking characteristics.

Materials and Methods

The investigation conforms to the Guide for the Care and Use of Laboratory Animals published by the National Institutes of Health (NIH Publication No. 85–23, revised 1996).

Index Patient

A 45-year-old black man with no history of cardiac disease presented to the hospital emergency department after a seizure. His initial ECG in the emergency department did not show ST segment abnormalities. He then became combative and had a run of monomorphic wide complex ventricular tachycardia. Lidocaine, 70 mg followed by a continuous infusion of 1 mg/min, was administered and led to ST...
segment elevation in V1 to V3. A slight right precordial ST elevation remained even 1 year after discontinuation of lidocaine.

Serial cardiac markers were negative for evidence of acute myocardial infarction. The patient did not have chest pain, and there was no evolution of ECG signs of infarction.

The wide complex ventricular tachycardia was hemodynamically destabilizing and was thus quickly shocked. The ventricular tachycardia was described as monomorphic based on single-lead ECG recordings from the emergency department and analysis by the cardiologist on duty. The lidocaine-induced ST segment elevation and the fact that the patient had a malignant arrhythmia and ST segment elevation unmasked by the Na channel blocker led to a diagnosis of BrS. Because of the unique characteristics of the case, the patient was referred for genotyping to determine the presence or absence of a channelopathy.

Mutational Analysis
The study was approved by the regional Institutional Review Board and written informed consent was obtained. Genomic DNA was isolated from peripheral blood leukocytes using a commercial kit (Gentra System; Puregene) as previously described. The exon and intron boundaries of the SCN5A gene were amplified and analyzed by direct sequencing. Polymerase chain reaction products were purified with a commercial reagent (ExoSAP-IT; USB) and were directly sequenced from both directions using an ABI PRISM 3100-Avant Automatic DNA sequencer.

Mutagenesis and Transfection of the TSA201 Cell Line
Mutant SCN5A channel cDNA was prepared using the megaprimer method for site-directed mutagenesis using the plasmid pcDNA3-SCN5A, which contains SCN5A cDNA cloned into pcDNA3.1 (+; Invitrogen, Carlsbad, Calif).

Mutated and wild-type (WT) sodium channels were expressed in the human embryonic kidney cell line TSA201 as previously described. Briefly, transient transfection was carried out with the calcium phosphate precipitation method using equimolar amounts of SCN5A cDNA (WT or mutant) and SCN1B cDNA subcloned into a pRc/cytomegalovirus vector. In addition, CD8 cDNA in a 2.4:1 molar ratio with SCN5A was cotransfected as a reporter gene to visually identify transfected cells using Dynabeads (M-450 CD8 Dynal). The cells were grown on polylysine-coated 35-mm culture dishes and placed in a temperature-controlled chamber for electrophysiological study (EPS; Medical Systems, Greenvale, NY). Channel characteristics were studied 72 hours after transfection.

Electrophysiology
Membrane currents were measured using a whole-cell patch clamp technique in transfected TSA201 cells in the absence and presence of lidocaine (Sigma Co). All recordings were obtained at room temperature (22°C) using an Axopatch 200B amplifier equipped with a CV-201A head stage (Axon Instruments). Macroscopic whole-cell Na+ current was recorded using perfusing bath solution containing (in mmol/L) 140 NaCl, 5 KCl, 1.8 CaCl2, 1 MgCl2, 2.8 Na Acetate, 10 HEPES, and 10 glucose (pH 7.3 with NaOH). Tetraethylammonium chloride (5 mmol/L) was added to the buffer to block TEA-sensitive native currents. Patch pipettes were pulled from borosilicate glass (7052; Model PP-89; Narashige) to obtain resistances between 1 and 2.5 mol/L. When filled with a solution containing (in mmol/L) 5 NaCl, 5 KCl, 130 CsF, 1.0 MgCl2, 5 EGTA, and 10 HEPES (pH 7.2 with CsO). Currents were filtered with a 4-pole Bessel filter at 5 kHz and digitized at 10 kHz.

Steady-state availability of the sodium channel was fitted to the Boltzmann equation, \( I_{\text{mem}} = I_0/(1 + \exp(V - V_{1/2})/k) \) where \( V_{1/2} \) and \( k \) are the midpoint and the slope factor, respectively, and \( V \) is the membrane potential.

All data acquisition and analysis were performed using the suite of pCLAMP programs V9.2 (Axon Instruments, Union City, Calif), EXCEL (Microsoft), and ORIGIN 6.1 (Microcal Software, Northampton, Mass).

Statistical Analysis
Data are expressed as mean±SEM. Two-tailed Student t test was performed using statistical software in SigmaPlot 2000 (Jandel Scientific Software). Differences were considered to be statistically significant at a value of \( P<0.05 \).

Results
Lidocaine-Induced Electrocardiogram-Like Brugada Syndrome
Figure 1A shows ST segment elevation in the right precordial leads recorded from the proband after intravenous adminis-
tration of 1 mg/kg lidocaine. The ECG shows a coved-type ST segment elevation >0.2 mV followed by a negative T wave after administration of lidocaine, typical for a Type 1 ECG phenotype in BrS.

DNA analysis revealed a novel double mutation in SCN5A (Figure 1B). The first was a single nucleotide substitution (g>a) involving codon 232 (gtc-to-atc) in exon 6 of SCN5A resulting in amino acid substitution of valine for isoleucine (V232I) located at the COOH terminus of the transmembrane segment S4 of domain I of the channel protein. The second missense mutation was a single nucleotide substitution (c>t) at 1308 (ctc-to-ttc) in exon 22 resulting in amino acid substitution of the leucine at position 1308 for a phenylalanine (L1308F). Interestingly, this amino acid is also located at the COOH terminus of the transmembrane segment S4 but in domain III (Figure 1C). The mutations were absent in over 400 references alleles from 200 ethnically matched controls.

**Biophysical Characteristics of Wild-Type and Double-Mutated (V232I/L1308F) SCN5A Channels**

Figure 2 illustrates the current–voltage relationship of the WT and double mutant channel expressed in TSA201 cells in the absence (A) and presence of 30 μmol/L lidocaine (B). Lidocaine more potently blocked the mutated channels. Representative currents in A and B were elicited by sequential test pulses at 0.06 Hz between −90 mV and −15 mV in increments of 5 mV from a holding potential of −120 mV (inset). C, Current–voltage (I-V) relationship in presence of 30 μmol/L lidocaine. D, Steady-state inactivation curves for WT and mutant channels in control. Symbols represent mean±SEM for 4 to 10 cells. Boltzmann analysis showed that the slope factor (k) and the half-inactivation potential (Hinf) did not differ significantly between groups.

Figure 2. Effect of lidocaine on I-V and steady-state inactivation in WT and V232I+L1308F channels. Sodium currents generated in mammalian TSA201 cells in the absence (A) and presence of 30 μmol/L lidocaine (B). Lidocaine more potently blocked the mutated channels. Representative currents in A and B were elicited by sequential test pulses at 0.06 Hz between −90 mV and −15 mV in increments of 5 mV from a holding potential of −120 mV (inset). C, Current–voltage (I-V) relationship in presence of 30 μmol/L lidocaine. D, Steady-state inactivation curves for WT and mutant channels in control. Symbols represent mean±SEM for 4 to 10 cells. Boltzmann analysis showed that the slope factor (k) and the half-inactivation potential (Hinf) did not differ significantly between groups.

Tonic Block

Blockade of sodium channels by lidocaine has been explained on the basis of the modulated receptor hypothesis,7,8 which proposes that opening of the channel increases accessibility of lidocaine to its binding site, which in turn stabilizes the channel in its inactivated state. As a consequence, the channel displays a dynamic block of higher affinity when channels are activated and subsequently inactivated and a lower-affinity tonic block in its resting state. To assess lidocaine tonic
block, we measured the effect of the drug on $I_{Na}$ at rest by holding the membrane at $-120$ mV for 15 seconds ($0.06$ Hz) before each measurement. Figure 4A shows $I_{Na}$ recordings elicited by a 20-ms pulse before and after exposure to $30 \mu$mol/L lidocaine. Tonic block was more important in $V232I$ with EC$_{50}$ values of $254 \pm 36 \mu$mol/L and $17 \pm 2 \mu$mol/L for tonic block in WT and $V232I$, respectively (Figure 4C).

### Use-Dependent Block

Use-dependent block (UDB) refers to potentiation of the blockade of $I_{Na}$ by lidocaine in which the frequency of the activating stimulus is increased. It is explained by the modulated receptor hypothesis as an increased accessibility of the drug to its binding site within the channel during rapid opening and closing of the channel that increase the number of channels blocked by lidocaine. UDB prolongs the refractory period in a rate-dependent fashion and is the basis for the antiarrhythmic action of lidocaine. We next compared the lidocaine UDB at depolarization frequencies of 0.2, 1, 2, and 10 Hz in WT and $V232I$ channels. Pulse duration was 20 ms, and the holding potential was $-120$ mV. Figure 4B depicts the onset of the use-dependent block caused by $10 \mu$mol/L lidocaine at stimulus frequencies of 2 and 10 Hz. Lidocaine caused little use-dependent block in WT channels, but potently blocked $V232I$ channels (Figure 4C–D). The concentration–response relationships, obtained from a standard Hill equation $1/(1+[\text{lidocaine}]/\text{EC}_{50})$, revealed that EC$_{50}$ for UDB of $V232I$ channels was shifted well into the therapeutic range of EC$_{50}$ for block of WT channels and remained considerably above it.

### Biophysical Characteristics of Separately Mutated $V232I$ and $L1308F$ SCN5A Channels

Ackerman et al$^9$ identified $L1308F$ as a polymorphism found mostly in Americans of African descent. To test for potentiation of the lidocaine block introduced by the $V232I$ substitution and this polymorphism, we separately tested the effects of each mutation. Blockade of $V232I$ and $L1308F$ peak current by $30 \mu$mol/L lidocaine was similar to the block in WT (29$\pm$2%; Figure 2C) with 25$\pm$9% and 21$\pm$3% reduction, respectively (Figure 5A); Figure 5B shows that half-inactivation voltage for $V232I$ and $L1308F$ was negatively shifted by $10 \pm 1$ mV ($n=4$) and $8 \pm 1$ mV ($n=5$), respectively, by $30 \mu$mol/L lidocaine. Thus, lidocaine had stronger effects on $V232I$ channel availability compared with WT and $L1308F$ ($V232I$ versus WT, $P<0.01$; $L1308F$ versus WT, $P=$ not significant). The lidocaine-induced shift in midinactivation potential ($H_{in50}$) of WT and $V232I$ channels as a function of lidocaine concentration. Double mutants are significantly different from the WT channel under the same dosage of lidocaine. *$P<0.05$.****
lidocaine’s EC$_{50}$ on WT was approximately 2 times lower than what we found for the single mutations L1308F and V232I (P<0.05) and approximately 9 times that of the double mutation (P=0.001).

Because UDB can be due to slower recovery from inactivation, we next compared recovery between mutated and WT channels using a double pulse protocol (Figure 7). Mutated channels exhibited recovery times similar to WT channels in control conditions (Table). Lidocaine delayed recovery from inactivation of the double mutant. A 2 exponential fit to the data (Figure 8) yielded similar time constants for V232I and L1308F, respectively, but slower than WT in presence of lidocaine (supplemental Table). Recovery for VI LF was 3-fold slower than each of the single mutation taken separately under 30 μmol/L lidocaine.

**Discussion**

Our results show that the V232I+L1308F double missense mutation in SCN5A produced no significant change in the current–voltage relationship, steady-state inactivation, or kinetics of I$_{Na}$, consistent with the lack of a disease phenotype in the patient under basal conditions. Despite the lack of any apparent alteration in gating parameters, V232I+L1308F channels displayed a larger reduction in I$_{Na}$ (73±0.09% for V232I+L1308F) versus WT (18.2±0.1%) during lidocaine tonic block (Figure 2C). These observations are consistent with the ability of lidocaine to induce the Brugada phenotype in this particular case.

Although steady-state inactivation of V232I+L1308F was no different from WT in control, 10 μmol/L lidocaine shifted half-inactivation of V232I+L1308F channels by −14.1±0.3 mV versus −4.8±0.3 mV for WT (Figure 3C). Such reduction in availability is likely to further contribute to the Brugada phenotype.

The changes in steady-state inactivation by lidocaine on each mutation seem additive because their sum nearly matches the shift observed in the double mutant. Similarly, UDB was larger and recovery from inactivation was slower in the double mutant as expected from an equal contribution by each mutation. These observations suggest independent additive effects by both mutations to potentiate the block by lidocaine.

Our results show that polymorphism L1308F confers a greater sensitivity of the cardiac sodium channel to blockade by lidocaine. One likely mechanism to explain the appearance of the BrS phenotype in this patient would be...
that L1308F lowered the threshold for arrhythmias in this patient and that the second mutation V232I, through an additive effect, brought this threshold in the therapeutic range for lidocaine. This is the first study showing that polymorphism L1308F confers a greater sensitivity of sodium channels to lidocaine. It demonstrates that, as previously shown for long QT syndrome, some polymorphisms may lead to drug-induced BrS.

V232I and L1308F are located at the intracellular end of S4-DI and the middle of S4-DIII, respectively. Both are remote from amino acids known to participate to the lidocaine receptor site.10–12 The transmembrane segment S4 contains positive charges that confer voltage dependence to activation of the channel. Neither mutation is expected to disrupt the pore of the channel, but they may be implicated in the opening of the channel.13–15 The movement of segment S4 in response to changes in membrane potential is also a strong modulator of the inactivation of the channel16–18 and potential interaction between S4 and S6 may modulate accessibility of lidocaine to its receptor site.16 Alanine scanning mutagenesis indicates that residues in S6 in domains I, III, and IV cates that residues in S6 in domains I, III, and IV (25.6 ± 8.9% versus 21.8 ± 2.9%, respectively). The transmembrane segment S4 in the activated configuration and increase the availability of the V232I channels. It may also contribute to use-dependent block because channels stimulated at higher rates spend more time in the activated states.

Clinical Relevance

The electrocardiographic manifestations of the congenital BrS can be unmasked by sodium channel blockers and several other conditions, including alcohol and cocaine toxicity.3–6,8 Pharmacological agents capable of unmasking the congenital syndrome are sodium channel blockers such as flecainide,3,4,37,38 pilsicainide,39 propafenone,41 ajmaline,3,4 and procainamide,3,29 psychotropic drugs such as amitriptyline,43,44 nortriptyline,42 desipramine,30 and clomipramine31 may also induce acquired forms of the BrS.

Figure 6. Effect of mutations L1308F (LF), V232I (VI), and V232I+L1308F (VI+LF) on lidocaine affinity for use-dependent block at 0.2 and 2 Hz. UDB was assessed as described in Figure 4. EC50 were obtained by measuring the reduction of peak current amplitude during each stimulus train and normalizing it to the maximal reduction. EC50 values (μmol/L) were 107.22 ± 20.25 (WT), 130.43 ± 23.89 (LF), 83.30 ± 25.79 (VI), and 12.17 ± 3.10 (VI+LF). At 2.0 Hz, EC50 values (μmol/L) were 70.88 ± 11.10 (WT), 33.92 ± 3.13 (LF), 34.41 ± 0.81 (VI), and 8.23 ± 0.42 (VI+LF). Statistical significance: *P<0.05 at 0.2 Hz versus VI+LF; *P<0.05, and **P<0.01 at 2.0 Hz versus WT. n=20; 11, 6 and 7 for WT, LF, VI, and VI+LF separately.
Most sodium channel blockers that act in this capacity are known to dissociate from the sodium channel with slow kinetics and induce strong use-dependent block typical of Class IC antiarrhythmic agents. In contrast, lidocaine and mexiletine (Class IB) display rapid dissociation kinetics and produce little to no ST segment elevation in patients with congenital BrS.4

We report a rare case of lidocaine-induced BrS phenotype in an individual who, to our knowledge, did not previously manifest the disease. The patient is shown to carry a double mutation in SCN5A capable of altering the interaction of lidocaine with the sodium channel so that the drug assumes characteristics of a Class IC agent, demonstrating potent use-dependent block of the sodium channel. Recently, Ackerman et al4 found mutation L1308F in one of 319 blacks but not among 295 whites. Our laboratory found it in one of 100 whites. The status of L1308F as a polymorphism remains to be determined; however, our results clearly indicate that this variant is an important determinant for the sensitivity of patients to lidocaine. Caution should therefore be exerted when treating carrier patients with Class I antiarrhythmic drugs. To our knowledge, this is the first demonstration of a compound mutation associated with an acquired or congenital form of BrS.

Figure 7. Effect of the double-mutation V232I+L1308F on the influence of lidocaine on recovery from inactivation. A, Effect of 30 μmol/L lidocaine on WT. B, Same as A for the double-mutant channel. Recovery from inactivation assessed by a double-pulse protocol (P1 to P2) consisting of 20 ms conditioning (P1) and test (P2) pulses to 0 mV separated by varying recovery intervals (ΔT) at −120 mV.

Figure 8. Modulation of the effects of lidocaine on recovery from inactivation by mutations V232I, L1308F and V232I+L1308F. Normalized peak current (P2/P1) were fitted to a double exponential function: y(t)=y0−A(1−exp[−t/τ1])+B(1−exp[−t/τ2]) where τ1 and τ2 represents the recovery time constant. The fitting parameters are shown in Table 1. n=11 to 16 cells per condition.
Sources of Funding
This work was supported by US National Institutes of Health grants HL47678 (CA) and HL66169 (RB) from the National Heart, Lung and Blood Institute; and grants from the American Heart Association (RB), National Heart Foundation, a program of the American Health Assistance Foundation (JMC), and NYS and Florida Grand Lodges, F. & A.M, Fondation Leducq, Que’bec, Canada (RB), Canadian Institutes of Health Research (CIHR) Grant #134443 (RD).

Disclosures
None.

References


Lidocaine-Induced Brugada Syndrome Phenotype Linked to a Novel Double Mutation in the Cardiac Sodium Channel

Hector M. Barajas-Martínez, Dan Hu, Jonathan M. Cordeiro, Yuesheng Wu, Richard J. Kovacs, Henry Meltser, Hong Kui, Burashnikov Elena, Ramon Brugada, Charles Antzelevitch and Robert Dumaine

Circ Res. 2008;103:396-404; originally published online July 3, 2008; doi: 10.1161/CIRCRESAHA.108.172619

Circulation Research is published by the American Heart Association, 7272 Greenville Avenue, Dallas, TX 75231
Copyright © 2008 American Heart Association, Inc. All rights reserved.
Print ISSN: 0009-7330. Online ISSN: 1524-4571

The online version of this article, along with updated information and services, is located on the World Wide Web at:
http://circres.ahajournals.org/content/103/4/396

Data Supplement (unedited) at:
http://circres.ahajournals.org/content/suppl/2008/07/03/CIRCRESAHA.108.172619.DC1

Permissions: Requests for permissions to reproduce figures, tables, or portions of articles originally published in Circulation Research can be obtained via RightsLink, a service of the Copyright Clearance Center, not the Editorial Office. Once the online version of the published article for which permission is being requested is located, click Request Permissions in the middle column of the Web page under Services. Further information about this process is available in the Permissions and Rights Question and Answer document.

Reprints: Information about reprints can be found online at:
http://www.lww.com/reprints

Subscriptions: Information about subscribing to Circulation Research is online at:
http://circres.ahajournals.org/subscriptions/
<table>
<thead>
<tr>
<th></th>
<th>Control</th>
<th></th>
<th>Lidocaine (30 µmol/L)</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>τ_f (ms)</td>
<td>A (%)</td>
<td>τ_s (ms)</td>
<td>B (%)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>WT</td>
<td>3 ± 1</td>
<td>80 ± 2</td>
<td>10 ± 4</td>
<td>20 ± 2</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>V232I</td>
<td>4 ± 1</td>
<td>78 ± 2</td>
<td>11 ± 3</td>
<td>23 ± 2</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>L1308F</td>
<td>4 ± 1</td>
<td>79 ± 3</td>
<td>11 ± 1</td>
<td>24 ± 5</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>V232I+L1308F</td>
<td>5 ± 1</td>
<td>67 ± 4</td>
<td>13 ± 2</td>
<td>43 ± 5</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>τ_f (ms)</td>
<td>A (%)</td>
<td>τ_s (ms)</td>
<td>B (%)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>WT</td>
<td>7 ± 1</td>
<td>77 ± 2</td>
<td>30 ± 2</td>
<td>23 ± 2</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>V232I</td>
<td>*12 ± 4</td>
<td>76 ± 3</td>
<td>33 ± 2</td>
<td>22 ± 3</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>L1308F</td>
<td>10 ± 1</td>
<td>80 ± 2</td>
<td>30 ± 3</td>
<td>24 ± 3</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>V232I+L1308F</td>
<td>*22 ± 2</td>
<td>*47 ± 3</td>
<td>*117 ± 7</td>
<td>*50 ± 5</td>
</tr>
</tbody>
</table>

**Online Table 1:** Parameters for recovery from inactivation obtained from a two exponential fit to data (Fig. 8) obtained from sodium current recordings elicited by a double pulse protocol as described in figure 7. Statistical significance * p < 0.05 mutant channel vs WT column wise.